Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Cantel Medical's Competitiveness

A competitive positioning analysis and financial ratio benchmarking of Cantel Medical (CMD) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q3 2021
Competitors Tracked
-
Publicly traded peers
Peer Group Market Share
100.00 %
vs 100.00 % a year ago
Revenue Growth Y/Y
32.51 %
Q3 2021
Net Margin
6.73 %
Q3 2021

Key Findings: Cantel Medical vs Its Competitors

  • TTM: Trailing 12-month revenue of 1,138M vs -M combined for tracked competitors (100.0% combined share).
  • Trending: Latest-quarter revenue run-rate is accelerating (+10.3% annualized vs trailing 12 months).
  • Peer revenue share: Cantel Medical accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

CMD Sales vs. its Competitors, Q3 2021

Cantel Medical generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.

API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/CMD/competitors
https://api.csimarket.com/api/v1/companies/CMD/relationships
https://api.csimarket.com/api/v1/companies/CMD/similar
Programmatic access for models, analytics, and integration workflows.

For context: the Medical Equipment & Supplies industry grew revenue 15.1% year over year, combined, vs 32.5% for Cantel Medical. Cantel Medical's share of combined industry revenue moved from 0.23% to 0.27%, a gain of 0.04 percentage points.

Cantel Medical's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity Profitable Expanding Above Industry Growth Distressed
Cantel Medical Corp Yes Yes Yes No
High-Confidence Competitors (14) 77% 79% 21% 15%

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

Market Share of the Peer Group, Q3 2021

100%market share
  • Cantel Medical100.0%
  • Competitors combined0.0%

Share of combined quarterly revenue of Cantel Medical and its 0 tracked competitors.

See Cantel Medical's full market share breakdown »

CMD Stock Performance relative to its Competitors

CMD Competitors (weighted) Percent change over the selected range

Cantel Medical's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.
40%beat U.S.A. 500
High-Confidence
(4 of 10)
Entity TTM Share Price Return
(group: median)
vs U.S.A. 500
Cantel Medical Corp - -
Competitors combined (0) 40.4% 63.2%
High-Confidence Competitors (10) 40.4% 63.2%
Similar-Size Competitors (0) 40.4% 63.2%
Similar Growth & Profitability (0) 40.4% 63.2%
Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Cantel Medical's competitor groups requires a Commercial License.

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

CMD Stock Performance relative to High-Confidence Competitors

CMD High-Confidence Competitors (equal-weighted, 14) Percent change over the selected range

Cantel Medical's Competitors Named by the Company

Competitive relationships identified from Cantel Medical reports and corroborating sources, each with a basis and confidence.
Competitor Basis Confidence Active Sources
Motus Gi Holdings Inc Company report 85% 2022 to 2026 3
Tomi Environmental Solutions Inc Company report 85% 2022 to 2026 3
Integra Lifesciences Holdings Corp Company report 85% 2022 to 2026 3
Ecolab Company report 85% 2022 to 2026 3
Stryker Company report 85% 2022 to 2026 3
Karl Storz Company report 85% 2022 to 2026 3
Skytron Company report 85% 2022 to 2026 3
BBraun Company report 85% 2022 to 2026 3
Contec Company report 85% 2022 to 2026 3
Getinge Company report 85% 2022 to 2026 3
Stilmas Company report 85% 2022 to 2026 3
Boston Scientific Company report 85% 2022 to 2026 3
Fedegari Company report 85% 2022 to 2026 3
Pentax Company report 85% 2022 to 2026 3
SteelCo Company report 85% 2022 to 2026 3
Wassenburg Company report 85% 2022 to 2026 3
Belimed Company report 85% 2022 to 2026 3
Crothall Company report 85% 2022 to 2026 3
Olympus Company report 85% 2022 to 2026 3
Ruhof Company report 85% 2022 to 2026 3
Baxter Company report 85% 2022 to 2026 3
Fortive Company report 85% 2022 to 2026 3
Agiliti Company report 85% 2022 to 2026 3
Berendsen plc Company report 85% 2022 to 2026 3
Owens & Minor Company report 85% 2022 to 2026 3
Techniplast Company report 85% 2022 to 2026 3
Northfield Company report 85% 2022 to 2026 3
Rentex Floren Company report 85% 2022 to 2026 3
MECO Company report 85% 2022 to 2026 3
Hill-Rom Company report 85% 2022 to 2026 3
CleanLease (Clean Lease Fortex) Company report 85% 2022 to 2026 3
Mobile Company report 85% 2022 to 2026 3
Rentex Awé Company report 85% 2022 to 2026 3
Sterilog Limited Company report 85% 2022 to 2026 3
Solventum Corporation Company report 85% 2022 to 2026 3
Mesa Laboratories Inc Company report 85% 2022 to 2026 3
Conmed Corporation Company report 85% 2022 to 2026 3
Aptargroup inc Company report 85% 2022 to 2026 3
Sotera Health Company Company report 85% 2022 to 2026 3
Danaher Corporation Company report 85% 2022 to 2026 3
Competitor Evidence Detail

Company report basis, confidence, active dates and source counts for Cantel Medical's named competitors require a Commercial License.

Methodology: relationships are extracted from Cantel Medical reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.

Cantel Medical's Business Segment Mix vs Peers

Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).
Company Largest Segment 2nd Segment 3rd Segment
Cantel Medical Corp Medical 47.40 % Dental 34.92 % Life Sciences 15.12 %

Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).

Get the full CSIMarket dataset: Subscribe API Connect Your AI